Regenerative Medicine Market Opportunities 2031
The regenerative medicine market was valued at US$ 11.77 billion in 2021 and is projected to reach US$ 37.48 billion by 2031; it is expected to grow at a CAGR of 17.9% from 2022 to 2031.
Regenerative medicine is an innovative field of medicine that develops methods for replacing/regenerating human cells, tissues, or organs to restore normal functions. It can heal tissues or organs by stimulating body's own repair mechanisms. Regenerative medicine allows scientists to grow tissues and organs in laboratory and safely implant them in the body when it cannot heal itself.
Increasing adoption of gene therapies, stem cell therapies, and tissue engineering; growing number of approvals for cell and gene therapies; and technological advancements in the field of regenerative medicine are the key factors driving the market growth. However, the high cost of these therapies is hampering the market expansion.
The regenerative medicine market is analyzed on the basis of type, application, and geography. The report offers insights and in-depth analysis of the regenerative medicine market, emphasizing various parameters such as market trends, technological advancements, and market dynamics, as well as the competitive landscape analysis of leading market players.
Strategic Insights
Market Insights
Increasing Number of Cell and Gene Therapy Approvals Bolsters Regenerative Medicine Market Growth
Growing number of cell and gene therapies is likely to drive the market growth. For instance, in May 2022, the US Food and Drug Administration (FDA) approved Novartis Kymriah CAR-T cell therapy for adult patients with relapsed or refractory (r/r) follicular lymphoma (FL). Kymriah is the first approved CAR-T cell therapy developed together by Novartis and the Perelman School of Medicine at the University of Pennsylvania. In February 2022, Janssen Biotech, Inc received US FDA approval for its CARVYKTI (ciltacabtagene autoleucel; cilta-cel) to treat adults with relapsed or refractory multiple myeloma.
- In August 2022, Bluebird Bio, Inc. received US FDA approval for its Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy to treat adults and pediatric patients suffering from beta-thalassemia who require red blood cell transfusions regularly.
- In March 2021, the US FDA approved Celgene Corporation’s Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to the treatment or whose disease has relapsed even after different types of therapies.
Type-Based Insights
Based on type, the regenerative medicine market is divided into cell-based immunotherapy and cell therapy products, tissue-engineered products, and gene therapy products. The cell-based immunotherapy and cell therapy products segment held the largest market share in 2021 and is expected to register the highest CAGR during the forecast period.
Application-Based Insights
Based on application, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, and diabetes. The oncology segment occupied the largest market share in 2021 and is speculated to register the highest CAGR during 2022–2031.
The COVID-19 pandemic created growth opportunities for the market players due to the urgency of developing new therapies for COVID-19 patients. Several research projects were initiated in the cell and gene therapy research industry. For instance, in November 2021, Longeveron Inc. initiated its phase 1 trial to test the safety of Longeveron Mesenchymal Stem Cells (LMSCs) in adults suffering from mild to severe acute respiratory distress syndrome (ARDS) due to COVID-19.
In 2022, North America held the largest share of the regenerative medicine market. The market growth is attributed to the rising research and development activities in the field of regenerative medicine. Asia Pacific is expected to register the fastest CAGR during the forecast period. China, Japan, and India are the major contributors to the regenerative medicine market in the region. The increasing stem cell research, rising government support for cell and gene research, and improvements in biotechnology infrastructure are the factors driving the market growth in APAC.
By geography, the regenerative medicine market is segmented into North America (The US, Canada, and Mexico), Europe (The UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (The UAE, Saudi Arabia, Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
Company Profiles
- Integra LifeSciences
- Gilead Sciences, Inc.
- Novartis AG
- Vericel Corporation
- Wright Medical Group N.V.
- MiMedx Group
- Osiris Therapeutics, Inc.
- Stryker Corporation
- Spark Therapeutics, Inc.
- Medtronic plc
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Type, Application, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Regenerative Medicine Market - By Type
1.3.2 Regenerative Medicine Market - By Application
1.3.3 Regenerative Medicine Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. REGENERATIVE MEDICINE MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. REGENERATIVE MEDICINE MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. REGENERATIVE MEDICINE MARKET - GLOBAL MARKET ANALYSIS
6.1. REGENERATIVE MEDICINE - GLOBAL MARKET OVERVIEW
6.2. REGENERATIVE MEDICINE - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. REGENERATIVE MEDICINE MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. CELL-BASED IMMUNOTHERAPY AND CELL THERAPY PRODUCTS
7.3.1. Overview
7.3.2. Cell-Based Immunotherapy and Cell Therapy Products Market Forecast and Analysis
7.3.3. Allogeneic Products Market
7.3.3.1. Overview
7.3.3.2. Allogeneic Products Market Forecast and Analysis
7.3.4. Autologous Products Market
7.3.4.1. Overview
7.3.4.2. Autologous Products Market Forecast and Analysis
7.4. TISSUE-ENGINEERED PRODUCTS
7.4.1. Overview
7.4.2. Tissue-Engineered Products Market Forecast and Analysis
7.5. GENE THERAPY PRODUCTS
7.5.1. Overview
7.5.2. Gene Therapy Products Market Forecast and Analysis
8. REGENERATIVE MEDICINE MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. MUSCULOSKELETAL DISORDERS
8.3.1. Overview
8.3.2. Musculoskeletal Disorders Market Forecast and Analysis
8.4. WOUND CARE
8.4.1. Overview
8.4.2. Wound Care Market Forecast and Analysis
8.5. ONCOLOGY
8.5.1. Overview
8.5.2. Oncology Market Forecast and Analysis
8.6. OCULAR DISORDERS
8.6.1. Overview
8.6.2. Ocular Disorders Market Forecast and Analysis
8.7. DIABETES
8.7.1. Overview
8.7.2. Diabetes Market Forecast and Analysis
9. REGENERATIVE MEDICINE MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Regenerative Medicine Market Overview
9.1.2 North America Regenerative Medicine Market Forecasts and Analysis
9.1.3 North America Regenerative Medicine Market Forecasts and Analysis - By Type
9.1.4 North America Regenerative Medicine Market Forecasts and Analysis - By Application
9.1.5 North America Regenerative Medicine Market Forecasts and Analysis - By Countries
9.1.5.1 United States Regenerative Medicine Market
9.1.5.1.1 United States Regenerative Medicine Market by Type
9.1.5.1.2 United States Regenerative Medicine Market by Application
9.1.5.2 Canada Regenerative Medicine Market
9.1.5.2.1 Canada Regenerative Medicine Market by Type
9.1.5.2.2 Canada Regenerative Medicine Market by Application
9.1.5.3 Mexico Regenerative Medicine Market
9.1.5.3.1 Mexico Regenerative Medicine Market by Type
9.1.5.3.2 Mexico Regenerative Medicine Market by Application
9.2. EUROPE
9.2.1 Europe Regenerative Medicine Market Overview
9.2.2 Europe Regenerative Medicine Market Forecasts and Analysis
9.2.3 Europe Regenerative Medicine Market Forecasts and Analysis - By Type
9.2.4 Europe Regenerative Medicine Market Forecasts and Analysis - By Application
9.2.5 Europe Regenerative Medicine Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Regenerative Medicine Market
9.2.5.1.1 Germany Regenerative Medicine Market by Type
9.2.5.1.2 Germany Regenerative Medicine Market by Application
9.2.5.2 France Regenerative Medicine Market
9.2.5.2.1 France Regenerative Medicine Market by Type
9.2.5.2.2 France Regenerative Medicine Market by Application
9.2.5.3 Italy Regenerative Medicine Market
9.2.5.3.1 Italy Regenerative Medicine Market by Type
9.2.5.3.2 Italy Regenerative Medicine Market by Application
9.2.5.4 Spain Regenerative Medicine Market
9.2.5.4.1 Spain Regenerative Medicine Market by Type
9.2.5.4.2 Spain Regenerative Medicine Market by Application
9.2.5.5 United Kingdom Regenerative Medicine Market
9.2.5.5.1 United Kingdom Regenerative Medicine Market by Type
9.2.5.5.2 United Kingdom Regenerative Medicine Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Regenerative Medicine Market Overview
9.3.2 Asia-Pacific Regenerative Medicine Market Forecasts and Analysis
9.3.3 Asia-Pacific Regenerative Medicine Market Forecasts and Analysis - By Type
9.3.4 Asia-Pacific Regenerative Medicine Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Regenerative Medicine Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Regenerative Medicine Market
9.3.5.1.1 Australia Regenerative Medicine Market by Type
9.3.5.1.2 Australia Regenerative Medicine Market by Application
9.3.5.2 China Regenerative Medicine Market
9.3.5.2.1 China Regenerative Medicine Market by Type
9.3.5.2.2 China Regenerative Medicine Market by Application
9.3.5.3 India Regenerative Medicine Market
9.3.5.3.1 India Regenerative Medicine Market by Type
9.3.5.3.2 India Regenerative Medicine Market by Application
9.3.5.4 Japan Regenerative Medicine Market
9.3.5.4.1 Japan Regenerative Medicine Market by Type
9.3.5.4.2 Japan Regenerative Medicine Market by Application
9.3.5.5 South Korea Regenerative Medicine Market
9.3.5.5.1 South Korea Regenerative Medicine Market by Type
9.3.5.5.2 South Korea Regenerative Medicine Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Regenerative Medicine Market Overview
9.4.2 Middle East and Africa Regenerative Medicine Market Forecasts and Analysis
9.4.3 Middle East and Africa Regenerative Medicine Market Forecasts and Analysis - By Type
9.4.4 Middle East and Africa Regenerative Medicine Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Regenerative Medicine Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Regenerative Medicine Market
9.4.5.1.1 South Africa Regenerative Medicine Market by Type
9.4.5.1.2 South Africa Regenerative Medicine Market by Application
9.4.5.2 Saudi Arabia Regenerative Medicine Market
9.4.5.2.1 Saudi Arabia Regenerative Medicine Market by Type
9.4.5.2.2 Saudi Arabia Regenerative Medicine Market by Application
9.4.5.3 U.A.E Regenerative Medicine Market
9.4.5.3.1 U.A.E Regenerative Medicine Market by Type
9.4.5.3.2 U.A.E Regenerative Medicine Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Regenerative Medicine Market Overview
9.5.2 South and Central America Regenerative Medicine Market Forecasts and Analysis
9.5.3 South and Central America Regenerative Medicine Market Forecasts and Analysis - By Type
9.5.4 South and Central America Regenerative Medicine Market Forecasts and Analysis - By Application
9.5.5 South and Central America Regenerative Medicine Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Regenerative Medicine Market
9.5.5.1.1 Brazil Regenerative Medicine Market by Type
9.5.5.1.2 Brazil Regenerative Medicine Market by Application
9.5.5.2 Argentina Regenerative Medicine Market
9.5.5.2.1 Argentina Regenerative Medicine Market by Type
9.5.5.2.2 Argentina Regenerative Medicine Market by Application
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL REGENERATIVE MEDICINE MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. REGENERATIVE MEDICINE MARKET, KEY COMPANY PROFILES
12.1. INTEGRA LIFESCIENCES CORPORATION
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. GILEAD SCIENCES
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. NOVARTIS
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. VERICEL CORPORATION
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. WRIGHT MEDICAL
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. MIMEDX
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. OSIRIS THERAPEUTICS
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. STRYKER CORPORATION
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. SPARK THERAPEUTICS
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. MEDTRONIC
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies
1. Integra LifeSciences Corporation
2. Gilead Sciences
3. Novartis
4. Vericel Corporation
5. Wright Medical
6. MiMedx
7. Osiris Therapeutics
8. Stryker Corporation
9. Spark Therapeutics
10. Medtronic
11. 3M
12. Allergan Plc
13. Aspect Biosystems
14. Bluebird Bio
15. Amgen, Inc.
16. Smith and Nephew Plc
17. Corestem, Inc.
18. Organogenesis
19. Kite Pharma
20. Spark Therapeutics
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For